Business Description
Arrowhead Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US04280A1007
Total Employee Number:
711Compare
Compare
Traded in other countries / regions
ARWR.USA0HI3.UKA2RR34.BrazilHDP1.GermanyARWR.Mexico Index Membership
Russell 2000Russell 3000 IPO Date
1995-02-01Description
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.63 | |||||
Equity-to-Asset | 0.22 | |||||
Debt-to-Equity | 2.11 | |||||
Debt-to-EBITDA | -7.36 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 3.97 | |||||
Beneish M-Score | -3.48 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 39 | |||||
3-Year EPS without NRI Growth Rate | 81.8 | |||||
3-Year Book Growth Rate | -3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -464.47 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.01 | |||||
9-Day RSI | 46.06 | |||||
14-Day RSI | 48.63 | |||||
3-1 Month Momentum % | 18.67 | |||||
6-1 Month Momentum % | 46.52 | |||||
12-1 Month Momentum % | 222.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.9 | |||||
Quick Ratio | 5.9 | |||||
Cash Ratio | 5.65 | |||||
Days Sales Outstanding | 28.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.6 | |||||
Shareholder Yield % | -2.45 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -33.82 | |||||
Net Margin % | -47.79 | |||||
EBITDA Margin % | -19.97 | |||||
FCF Margin % | -11.22 | |||||
OCF Margin % | -8.82 | |||||
ROE % | -60.68 | |||||
ROA % | -18.28 | |||||
ROIC % | -40.6 | |||||
3-Year ROIIC % | 179.26 | |||||
ROC (Joel Greenblatt) % | -37.61 | |||||
ROCE % | -10.73 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 2263.42 | |||||
PS Ratio | 17.76 | |||||
PB Ratio | 25.72 | |||||
Price-to-Tangible-Book | 26.03 | |||||
EV-to-EBIT | -71.29 | |||||
EV-to-Forward-EBIT | 4.31 | |||||
EV-to-EBITDA | -85.05 | |||||
EV-to-Forward-EBITDA | -19.14 | |||||
EV-to-Revenue | 16.98 | |||||
EV-to-Forward-Revenue | 26.21 | |||||
EV-to-FCF | -151.36 | |||||
Price-to-GF-Value | 1.63 | |||||
Price-to-Median-PS-Value | 0.68 | |||||
| Price-to-Net-Current-Asset-Value | 471.44 | |||||
Earnings Yield (Greenblatt) % | -1.4 | |||||
FCF Yield % | -0.63 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ARWR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arrowhead Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 669.495 | ||
| EPS (TTM) ($) | -2.25 | ||
| Beta | 2.0601 | ||
| 3-Year Sharpe Ratio | 0.79 | ||
| 3-Year Sortino Ratio | 1.56 | ||
| Volatility % | 61.76 | ||
| 14-Day RSI | 48.63 | ||
| 14-Day ATR ($) | 3.269252 | ||
| 20-Day SMA ($) | 86.8025 | ||
| 12-1 Month Momentum % | 222.6 | ||
| 52-Week Range ($) | 27.15 - 95.4899 | ||
| Shares Outstanding (Mil) | 141.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arrowhead Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arrowhead Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| First quarter earnings conference call for 2027 | 2027-02-05 16:30 | In 150 days | ||
| First quarter earnings results for 2027 | 2027-02-05 | In 149 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-11-25 16:30 | In 78 days | ||
| Annual report for 2026 | 2026-11-25 | In 77 days | ||
| Fourth quarter earnings results for 2026 | 2026-11-25 | In 77 days | ||
| H.C. Wainwright 28th Annual Global Investment Conference | 2026-09-16 09:00 | In 8 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-15 11:30 | In 7 days | ||
| Guidance call for 2026 | 2026-09-10 10:55 | In 2 days | ||
| Review SHASTA-3 and SHASTA-4 pivotal trial 12-month results | 2026-08-31 08:00 | 84.91 (-3.50%) | ||
| HOT LINE 9 Late Breaker Session | 2026-08-30 16:30 | 84.91 (-3.50%) |
Show
Entries
Arrowhead Pharmaceuticals Inc Frequently Asked Questions
What is Arrowhead Pharmaceuticals Inc(ARWR)'s stock price today?
The current price of ARWR is $84.86. The 52 week high of ARWR is $95.49 and 52 week low is $27.15.
When is next earnings date of Arrowhead Pharmaceuticals Inc(ARWR)?
The next earnings date of Arrowhead Pharmaceuticals Inc(ARWR) is 2026-11-25 Est..
Does Arrowhead Pharmaceuticals Inc(ARWR) pay dividends? If so, how much?
Arrowhead Pharmaceuticals Inc(ARWR) does not pay dividend.
Press Release
Articles on Arrowhead Pharmaceuticals Inc
Headlines
See More- 1
Sep 08, 2026
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades
Seeking Alpha • 9:26am
Aug 30, 2026
Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies
Seeking Alpha • 11:30am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers